Page last updated: 2024-12-05

chromonar

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Chromonar is a synthetic flavonoid compound with potential antioxidant and anti-inflammatory properties. It is derived from the chromone scaffold and has been studied for its potential therapeutic applications in conditions such as cardiovascular disease, neurodegenerative disorders, and cancer. Research suggests that chromonar may exhibit antioxidant activity by scavenging free radicals and inhibiting lipid peroxidation. It has also been shown to possess anti-inflammatory effects by inhibiting the production of inflammatory mediators. The exact mechanism of action of chromonar is not fully understood, but its potential therapeutic benefits warrant further investigation.'

Chromonar: A coronary vasodilator agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12604
CHEMBL ID163672
CHEBI ID135525
SCHEMBL ID309094
MeSH IDM0004398

Synonyms (50)

Synonym
chromonar
carbocromenum [inn-latin]
einecs 212-356-6
carbocromene [inn-french]
carbochromene
carbocromeno [inn-spanish]
acetic acid, ((3-(2-(diethylamino)ethyl)-4-methyl-2-oxo-2h-1-benzopyran-7-yl)oxy)-, ethyl ester
carbocromen
brn 1691147
carbocromen (inn)
804-10-4
D07619
nsc110430
ethyl 2-[3-(2-diethylaminoethyl)-4-methyl-2-oxo-chromen-7-yl]oxyacetate
karbokromen (russian)
carbochromen
[[3-[2-(diethylamino)ethyl]-4-methyl-2-oxo-2h-1-benzopyran-7-yl]oxy]acetic acid, ethyl ester, hydrochloride
3-[.beta.-(diethylamino)ethyl]-4-methyl-7-(carbethoxymethoxy)-coumarin hydrochloride
carbocromene
casella 4489
ethyl ((3-(2-(diethylamino)ethyl)-4-methyl-2-oxo-2h-chromen-7-yl)oxy)acetate
OPREA1_632400
CHEBI:135525
CHEMBL163672
carbocromeno
r0c9nie5jj ,
carbocromen [inn]
carbocromenum
5-18-12-00048 (beilstein handbook reference)
unii-r0c9nie5jj
carbocromen [who-dd]
a-27053 free base
nsc-110430 free base
((3-(2-(diethylamino)ethyl)-4-methyl-2-oxo-2h-1-benzopyran-7-yl)oxy)acetic acid ethyl ester
chromonar [mi]
ag-3 free base
SCHEMBL309094
DTXSID60230301
diammoniumhydrogencitrate
KLOIYEQEVSIOOO-UHFFFAOYSA-N
ethyl ({3-[2-(diethylamino)ethyl]-4-methyl-2-oxo-2h-chromen-7-yl}oxy)acetate
FT-0715144
ethyl 2-(3-(2-(diethylamino)ethyl)-4-methyl-2-oxo-2h-chromen-7-yloxy)acetate
Q5037872
beta-diethylaminoethyl-4-methyl-7-ethoxycarbonylmethoxy coumarin
DB13279
ethyl 2-[3-[2-(diethylamino)ethyl]-4-methyl-2-oxochromen-7-yl]oxyacetate
carbochromen; carbochromene
ethyl 2-({3-[2-(diethylamino)ethyl]-4-methyl-2-oxo-2h-chromen-7-yl}oxy)acetate
EN300-19767864

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Pretreatment of the animals (3--5 weeks) with carbocromen leads to strong protection against toxic effects of digoxin even 16--20 h after last dosing."( [The effects of oral carbocromen on the therapeutic and toxic effects of digitalis].
Fiedler, VB; Göbel, H; Scholtholt, J, 1980
)
0.26

Bioavailability

ExcerptReferenceRelevance
" To investigate the ocular bioavailability of cloricromene after inclusion in the polymer matrix, the new nanoparticle system was topically administered in the rabbit eye and compared with an aqueous solution of the same drug."( Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene.
Bucolo, C; Busà, B; Maltese, A; Maugeri, F; Pignatello, R; Puglisi, G, 2004
)
0.32
" Based on the technological results, AD6-loaded Eudragit Retard nanoparticle suspensions appear to offer promise as a means to improving the shelf life and bioavailability of this drug after ophthalmic application."( Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene.
Bucolo, C; Maltese, A; Maugeri, F; Pignatello, R; Puglisi, G; Ricupero, N, 2006
)
0.33

Dosage Studied

ExcerptRelevanceReference
" When keeping the heart rate constant by means of a pace maker, carbocromen even at higher dosage caused a clear-cut improvement."( [The effect of carbocromen on the ST segment of the epicardial electrocardiogram in a model of intermitting myocardial ischemia (author's transl)].
Kunath, B; Nitz, RE; Scholtholt, J; Sirbulescu, R, 1976
)
0.26
"The profile of cumulative amount released from a solid dosage form, observed in an in vitro liberation apparatus, represents the cumulative frequency of the residence times of drug molecules in the galenic formulation."( In vitro--in vivo correlation, a time scaling problem? Basic considerations on in vitro dissolution testing.
Brockmeier, D; von Hattingberg, HM, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
coumarins
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID179235Compound was tested for the vasorelaxation in rat aorta rings pre-contracted with noradrenaline (NA) 10 uM2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Synthesis and vasorelaxant activity of new coumarin and furocoumarin derivatives.
AID640615Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
AID179234Compound was tested for the vasorelaxation in rat aorta rings pre-contracted with KCl 60 mM2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Synthesis and vasorelaxant activity of new coumarin and furocoumarin derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (175)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990115 (65.71)18.7374
1990's37 (21.14)18.2507
2000's17 (9.71)29.6817
2010's5 (2.86)24.3611
2020's1 (0.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.41 (24.57)
Research Supply Index5.35 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (5.00%)5.53%
Reviews1 (0.50%)6.00%
Case Studies6 (3.00%)4.05%
Observational0 (0.00%)0.25%
Other183 (91.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]